Results 221 to 230 of about 5,782 (258)
Some of the next articles are maybe not open access.
T cell-engaging therapies — BiTEs and beyond
Nature Reviews Clinical Oncology, 2020Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) therapy, considering the unprecedented new indication for such therapy in combating minimal (or ...
Maria-Elisabeth Goebeler, Ralf C. Bargou
openaire +2 more sources
Bispecific T‐cell engagers for treatment of multiple myeloma
American Journal of Hematology, 2022AbstractBispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B cell maturation antigen (BCMA) and differ among themselves ...
Gayathri Ravi, Luciano J. Costa
openaire +2 more sources
Management of T-Cell Engaging Immunotherapy Complications
The Cancer Journal, 2019Abstract The advent of T-cell–mediated immunotherapy has led to a new era in the treatment of relapsed, refractory B-cell lymphomas and leukemias. Chimeric antigen receptor T-cell and engineered T-cell receptor therapies have demonstrated impressive efficacy in treating refractory disease.
Indumathy, Varadarajan, Daniel W, Lee
openaire +2 more sources
T-cell Engagers in Prostate Cancer
European UrologyOwing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 ...
Chadi, Hage Chehade +9 more
openaire +2 more sources
T-cell engaging antibodies for B-cell lymphomas
Seminars in HematologyT-cell engaging bispecific antibodies (BsAbs) have transformed the treatment paradigms for B-cell non-Hodgkin lymphomas. This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas.
Dong Hyun, Kim, Tae Min, Kim
openaire +2 more sources
An Engaging Question of T Cell Receptors
Science's STKE, 2000Signal desensitization occurs through several mechanisms involving the inhibition of receptors, intracellular signal mediators, or nuclear transcription factors. Cross-linking of the T cell receptor (TCR) leads to receptor activation followed by rapid desensitization. TCR internalization occurs through protein tyrosine kinase-dependent and
openaire +2 more sources
Blinatumomab: A novel, bispecific, T-cell engaging antibody
American Journal of Health-System Pharmacy, 2016The pharmacology, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, safety and tolerability, and place in therapy of blinatumomab are reviewed.Blinatumomab is a novel, bispecific, T-cell engaging antibody that targets tumor-associated antigens CD19 and CD3.
Megan Brafford, May, Ashley, Glode
openaire +2 more sources
Quantitative Pharmacology Methods for Bispecific T Cell Engagers
Bulletin of Mathematical BiologyAbstract T Cell Engager (TCE)s are an exciting therapeutic modality in immuno-oncology that acts to bypass antigen presentation and forms a direct link between cancer and immune cells in the Tumor Microenvironment (TME). TCEs are efficacious only when the drug is bound to both immune and cancer cell targets.
Mahdiar Sadeghi +3 more
openaire +2 more sources
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Cancer Research, 2009Abstract There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected ...
Patrick A, Baeuerle, Carsten, Reinhardt
openaire +2 more sources
Clinical Experience with Bispecific T Cell Engagers
2019Bispecific T cell engagers are antibody constructs directed to a tumor-specific target on the one hand and to CD3-positive T cells on the other hand. Blinatumomab is a compound with specificity for the pan-B cell marker CD19. Clinical activity was tested in relapsed and refractory (R/R) non-Hodgkin's Lymphoma (NHL), R/R acute lymphoblastic leukemia ...
openaire +2 more sources